Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel

Phase 1

Withdrawn

Conditions: Cancer
Non Small Cell Lung Cancer
Epithelial Ovarian Cancer

Interventions: Drug: AZD0530
Drug: Carboplatin
Drug: paclitaxel

First Posted Date: 2009-10-23

Last Posted Date: 2010-02-04

Lead Sponsor: AstraZeneca

Target Recruit Count: 27

Registration Number: NCT01000896

Locations: 🇯🇵
Research Site, Fukuoka, Japan

Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy

Phase 2

Withdrawn

Conditions: Lung Cancer

First Posted Date: 2009-10-20

Last Posted Date: 2012-03-06

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Registration Number: NCT00998101

A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung

Phase 2

Completed

Conditions: Metastatic or Recurrent Squamous Cell Carcinoma of the Lung

First Posted Date: 2009-10-20

Last Posted Date: 2016-03-31

Lead Sponsor: Oncolytics Biotech

Target Recruit Count: 32

Registration Number: NCT00998192

Locations: 🇺🇸
Ocala Oncology Center, Ocala, Florida, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Illinois Cancer Specialists, Niles, Illinois, United States

and more 14 locations

Study of Adding Cetuximab to Chemotherapy for the Treatment of Advanced and/or Recurrent Cervical Cancer

Phase 2

Active, not recruiting

Conditions: Cervical Cancer

Interventions: Drug: paclitaxel
Drug: carboplatin
Drug: cetuximab

First Posted Date: 2009-10-16

Last Posted Date: 2023-11-14

Lead Sponsor: National Cancer Institute, Naples

Target Recruit Count: 108

Registration Number: NCT00997009

Locations: 🇮🇹
Ospedale Senatore Antonio Perrino, Brindisi, Italy
🇮🇹
Ospedale Oncologico A. Businco, Cagliari, Italy
🇮🇹
A.O. Unversitaria Policlinico, Modena, Italy

and more 11 locations

A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas

Phase 2

Completed

Conditions: Glioblastoma Multiforme
Gliosarcoma
Anaplastic Astrocytoma
Anaplastic Oligodendroglioma
Anaplastic Mixed Oligoastrocytoma

Interventions: Drug: ZD6474 (Vandetanib)
Drug: Carboplatin

First Posted Date: 2009-10-14

Last Posted Date: 2016-03-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 112

Registration Number: NCT00995007

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Metastatic Cancer
Ovarian Cancer
Peritoneal Cavity Cancer

Interventions: Drug: cisplatin
Drug: carboplatin
Drug: paclitaxel

First Posted Date: 2009-10-12

Last Posted Date: 2023-08-28

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 275

Registration Number: NCT00993655

Locations: 🇺🇸
Women and Infants Hospital of Rhode Island, Providence, Rhode Island, United States
🇨🇦
London Regional Cancer Program, London, Ontario, Canada
🇺🇸
CoxHealth, Springfield, Missouri, United States

and more 47 locations

Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Ovarian Clear Cell Cystadenocarcinoma
Ovarian Serous Cystadenocarcinoma
Ovarian Undifferentiated Adenocarcinoma
Brenner Tumor
Ovarian Endometrioid Adenocarcinoma
Ovarian Mucinous Cystadenocarcinoma
Primary Peritoneal Cavity Cancer
Recurrent Ovarian Epithelial Cancer
Ovarian Mixed Epithelial Carcinoma

Interventions: Drug: belinostat
Drug: carboplatin

First Posted Date: 2009-10-12

Last Posted Date: 2019-07-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 29

Registration Number: NCT00993616

Locations: 🇺🇸
Green Bay Oncology - Oconto Falls, Oconto Falls, Wisconsin, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Women's Cancer Center of Nevada, Las Vegas, Nevada, United States

and more 78 locations

CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: CS-1008
Drug: Placebo
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2009-10-08

Last Posted Date: 2012-09-10

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 109

Registration Number: NCT00991796

Locations: 🇩🇪
Asklepios Fachkliniken Munchen Gauting, Gauting, Germany
🇩🇪
Zentrum fur Pneumologie und Thoraxchirurgie, Grobhansdorf, Germany

A Study to Document Long-Term Safety and Continued Benefit of Irinotecan and Carboplatin or Irinotecan in Subjects With Refractory Solid Tumors (Rollover Study -001, -002)

Phase 1

Completed

Conditions: Pediatric Solid Tumors

Interventions: Drug: Irinotecan
Drug: Carboplatin

First Posted Date: 2009-10-07

Last Posted Date: 2010-02-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 20

Registration Number: NCT00990912

Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1

Completed

Conditions: Fallopian Tube Carcinoma
Fallopian Tube Carcinosarcoma
Fallopian Tube Endometrioid Adenocarcinoma
Fallopian Tube Transitional Cell Carcinoma
Ovarian Clear Cell Adenocarcinoma
Ovarian Serous Adenocarcinoma
Ovarian Transitional Cell Carcinoma
Primary Peritoneal Serous Adenocarcinoma
Fallopian Tube Clear Cell Adenocarcinoma
Fallopian Tube Mucinous Adenocarcinoma

Interventions: Biological: Bevacizumab
Drug: Carboplatin
Drug: Cisplatin
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Drug: Veliparib

First Posted Date: 2009-10-05

Last Posted Date: 2021-10-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 431

Registration Number: NCT00989651

Locations: 🇺🇸
MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore, Maryland, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

and more 20 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy